&w=3840&q=100)
Looking for dividends? Keep an eye on these 27 stocks today; full list here
Notably, the ex-date refers to the day when a stock begins trading without the entitlement to dividend payouts. Therefore, investors who wish to receive the dividend must own the stock before the ex-date. The companies, however, finalise the list of eligible shareholders for the dividend payout on the record date.
Among the listed companies, MCX, CEAT, and Alldigi Tech have announced the highest dividend reward for their respective shareholders. They have declared a dividend of ₹30 per share. Additionally, these three companies have set the record date on August 8, 2025, to determine shareholder eligibility for the dividend.
Among others, CAMS has announced an interim dividend of ₹11 per share, Hindalco Industries has declared a final dividend (for FY25) of ₹5 per share, and Indian Oil Corporation has announced an interim dividend of ₹3 per share for its shareholders. They have all set their record date on August 8 for determining shareholders' eligibility for the said announcements.
Here is the complete list of stocks that will remain in focus today as they trade ex-dividend on August 8, along with their key details:
Company Ex-date Announcement Record date
B India Aug 8, 2025 Interim Dividend - ₹9.7700 Aug 8, 2025
Alkem Laboratories Aug 8, 2025 Final Dividend - ₹8 Aug 8, 2025
Alldigi Tech Aug 8, 2025 Interim Dividend - ₹30 Aug 8, 2025
Aurobindo Pharma Aug 8, 2025 Interim Dividend - ₹4 Aug 8, 2025
Computer Age Management Services Aug 8, 2025 Interim Dividend - ₹11 Aug 8, 2025
Ceat Aug 8, 2025 Final Dividend - ₹30 Aug 8, 2025
Delta Corp Aug 8, 2025 Final Dividend - ₹1.2500 Aug 8, 2025
Flair Writing Industries Aug 8, 2025 Final Dividend - ₹1 Aug 8, 2025
Gujarat Containers Aug 8, 2025 Final Dividend - ₹1.50 Aug 8, 2025
Gujarat Hotels Aug 8, 2025 Final Dividend - ₹3 Aug 8, 2025
Hindalco Industries Aug 8, 2025 Final Dividend - ₹5 Aug 8, 2025
Indo Thai Securities Aug 8, 2025 Interim Dividend - ₹0.10 Aug 8, 2025
Indian Oil Corporation Aug 8, 2025 Final Dividend - ₹3 Aug 8, 2025
Jtekt India Aug 8, 2025 Final Dividend - ₹0.70 Aug 9, 2025
Kronox Lab Sciences Aug 8, 2025 Final Dividend - ₹0.50 Aug 8, 2025
Mankind Pharma Aug 8, 2025 Interim Dividend - ₹1 Aug 8, 2025
Matrimony.com Aug 8, 2025 Final Dividend - ₹5 Aug 8, 2025
Multi Commodity Exchange of India Aug 8, 2025 Dividend - ₹30 Aug 8, 2025
Oriental Aromatics Aug 8, 2025 Final Dividend - ₹0.50 Aug 8, 2025
Paras Defence and Space Technologies Aug 8, 2025 Final Dividend - ₹0.50 Aug 8, 2025
Premco Global Aug 8, 2025 Interim Dividend - ₹4 Aug 8, 2025
Quess Corp Aug 8, 2025 Final Dividend - ₹6 Aug 8, 2025
Shilchar Technologies Aug 8, 2025 Final Dividend - ₹12.50 Aug 8, 2025
Shradha AI Technologies Aug 8, 2025 Final Dividend - ₹0.60 Aug 8, 2025
Sonata Software Aug 8, 2025 Interim Dividend - ₹1.2500 Aug 8, 2025
Steelcast Aug 8, 2025 Interim Dividend - ₹1.80 Aug 8, 2025
Varroc Engineering Aug 8, 2025 Final Dividend - ₹1 Aug 8, 2025
Vishnu Chemicals Aug 8, 2025 Final Dividend - ₹0.30 Aug 8, 2025
Voith Paper Fabrics India Aug 8, 2025 Final Dividend - ₹10 Aug 8, 2025
Wonderla Holidays Aug 8, 2025 Final Dividend - ₹2 Aug 8, 2025
ZF Commercial Vehicle Control Systems India Aug 8, 2025 Final Dividend - ₹19 Aug 8, 2025
(Source: BSE)
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
4 hours ago
- Economic Times
Adani Power wins $3-b Bihar thermal project
Synopsis Adani Power secured a tender to establish and manage a 2,400 MW thermal power plant in Bihar, investing $3 billion. The company bid ₹6.075 per unit for power supply, with the project operating under a design, build, finance, own, and operate model. This initiative is expected to create substantial employment opportunities during construction and operation. Agencies Adani Power said Thursday it won a tender to develop and operate a 2,400 MW new thermal power plant in Bihar, with an investment of $3 company bid ₹6.075 per unit for the supply of power from the project, it said in customary exchange filings. As part of the contract, Adani Power would supply electricity from the ultra-supercritical generation plant to state distribution project would be set up under the design, build, finance, own, and operate model. The first unit would be commissioned within 48 months, and the last within 60 months, the company said."Our plant will... supply dependable, competitively priced, and high-quality power to the state," said SB Khyalia, chief executive officer, Adani Power. The plant will receive fuel from the allocated coal linkage under the Centre's Shakti Policy. The project is expected to generate direct and indirect employment of 10,000-12,000 during the construction phase and 3,000 once it is operational, Adani Power Power's scrip ended at ₹578.50, up 2.05% on the BSE, on Thursday.
Economic Times
5 hours ago
- Economic Times
Emcure Pharmaceuticals reports 41% surge in Q1 net profit driven by strong domestic and international growth
Emcure Pharmaceuticals reported a strong first quarter with a 41% increase in net profit, reaching Rs 215 crore, and a 16% rise in revenue to Rs 2,101 crore. Growth was fueled by robust domestic and international performance, particularly in the rest of the world and Canada. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Pune-based Emcure Pharmaceuticals on Thursday reported a 41% year-on-year increase in first quarter net profit at Rs 215 from operations rose 16% to Rs 2,101 crore, driven by robust performance in domestic and international businesses. The company's EBITDA margins for April-June stood at 19.2% with EBITDA up 20.1% YoY. International business grew 22%, while the rest of the world business grew 42%. The company's Canada business grew 16.4% led by new launches and market share gains. Europe saw early benefits of new launches and grew 12.8%.'We continue to augment our portfolio in all our focus markets through in-licensing and in-house development,' said Satish Mehta, CEO and managing director, Emcure Pharmaceuticals Its domestic business grew 9.4% led by strong performance in all out key therapies and aided by new initiatives in derma and the quarter, the company strengthened its domestic business through expansion of its strategic partnership with Sanofi. Going forward, Emcure will be marketing and distributing Sanofi's oral anti-diabetic portfolio in addition to the cardiovascular portfolio.'The expanded Sanofi partnership positions us well in the fast-growing metabolic segment. We also have a strong product pipeline for both our domestic and international markets, which will fuel future growth. We remain focused on improving efficiencies to drive sustained improvement in margins,' Mehta of Emcure Pharmaceuticals closed 1.58% lower at Rs 1,398.80 apiece on the BSE on Thursday. The company announced the earnings during market hours.
Time of India
5 hours ago
- Time of India
Emcure Pharmaceuticals reports 41% surge in Q1 net profit driven by strong domestic and international growth
Pune-based Emcure Pharmaceuticals on Thursday reported a 41% year-on-year increase in first quarter net profit at Rs 215 crore. Revenue from operations rose 16% to Rs 2,101 crore, driven by robust performance in domestic and international businesses. The company's EBITDA margins for April-June stood at 19.2% with EBITDA up 20.1% YoY. International business grew 22%, while the rest of the world business grew 42%. The company's Canada business grew 16.4% led by new launches and market share gains. Europe saw early benefits of new launches and grew 12.8%. 'We continue to augment our portfolio in all our focus markets through in-licensing and in-house development,' said Satish Mehta, CEO and managing director, Emcure Pharmaceuticals. Its domestic business grew 9.4% led by strong performance in all out key therapies and aided by new initiatives in derma and OTC. During the quarter, the company strengthened its domestic business through expansion of its strategic partnership with Sanofi. Going forward, Emcure will be marketing and distributing Sanofi's oral anti-diabetic portfolio in addition to the cardiovascular portfolio. 'The expanded Sanofi partnership positions us well in the fast-growing metabolic segment. We also have a strong product pipeline for both our domestic and international markets, which will fuel future growth. We remain focused on improving efficiencies to drive sustained improvement in margins,' Mehta said. Shares of Emcure Pharmaceuticals closed 1.58% lower at Rs 1,398.80 apiece on the BSE on Thursday. The company announced the earnings during market hours.
